Mirna Therapeutics to Present at the BIO CEO & Investor and LEERINK Global Healthcare Conferences in February
Mirna Therapeutics, Inc. (Nasdaq: MIRN), a clinical-stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics, today announced its participation in two healthcare investor conferences during the month of February.
The 18th Annual BIO CEO & Investor
On Tuesday, February 9, 2016, President and CEO Paul Lammers, M.D., M.Sc., will present a corporate overview at 11:00 AM EST. The conference is being held at the Waldorf Astoria in New York City.
LEERINK Partners 5th Annual Global
On Thursday, February 11, 2016, Dr. Lammers will participate in a fireside chat to discuss recent corporate developments at 3:05 PM EST. The conference is being held at the Waldorf Astoria in New York City.
The BIO CEO presentation will be webcast live and may be accessed from the Events & Presentations section of the Company's website. An archived version of the webcast will be available for replay following the event.
About Mirna Therapeutics, Inc.
Mirna is a clinical-stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics and is the first to establish clinical proof-of-concept for a microRNA replacement therapy for cancer. Mirna's lead product candidate, MRX34, a mimic of naturally occurring microRNA-34 (miR-34), is currently being studied in a Phase 1 clinical trial in patients with primary liver cancer, advanced solid tumors and hematological malignancies. miR-34 is one of the most widely published microRNAs and is considered a key regulator of multiple oncogenes across key oncogenic pathways, with the capacity to regulate more than 30 different oncogenes and repress the immune checkpoint signaling molecule PD-L1. The potential capacity to simultaneously affect multiple pathways and processes that are critical to cancer cell viability may make mimics of tumor suppressor microRNAs potent anti-cancer agents and less susceptible to drug resistance. Mirna plans to develop MRX34 as a monotherapy and in combination with other therapeutic modalities, such as targeted therapies and immuno-oncology agents. The company was founded in 2007 and is located in Austin, Texas.
For more information, visit www.mirnarx.com.